Cargando…
Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran
Idarucizumab is the first targeted antidote of dabigatran, a direct oral anticoagulant used for prevention and treatment of venous thromboembolism and prevention of stroke in atrial fibrillation. Idarucizumab is a humanized fragment of a monoclonal antibody, which binds dabigatran reversibly with hi...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876800/ https://www.ncbi.nlm.nih.gov/pubmed/27274201 http://dx.doi.org/10.2147/DDDT.S94167 |